The inhaler, with an older propellant, is already approved in Europe for the treatment of adults with chronic obstructive ...

AstraZeneca said on Thursday its experimental therapy, gefurulimab, met the primary goal and all secondary endpoints in a ...

The pharma sees the drug, gefurulimab, as a more convenient, self-administered alternative to the infused medicines it sells ...

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030, it said on ...

In a vote of confidence for Virginia’s growing life sciences sector, pharmaceutical giant AstraZeneca announced plans to ...

On July 21, AstraZeneca said it would invest $50 billion in U.S. production by 2030. At the core is a manufacturing plant to ...

UK-based pharmaceutical giant AstraZeneca plans to build its largest drug manufacturing facility in Virginia, creating ...

AstraZeneca has increased its investment in U.S. operations more than 14-fold, committing $50 billion to a range of ...

British biopharmaceutical giant AstraZeneca plans to invest $50 billion in the United States by 2030, expanding its presence ...

The $50 billion target, which AstraZeneca plans to meet by 2030, includes new manufacturing projects in Virginia and ...

AstraZeneca's shares are up 3.5% over the year to date but remain down 11% over the past 52 weeks.

AstraZeneca plans to spend $50 billion to expand manufacturing and research capabilities in the U.S. by 2030.